US4440764A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Water soluble esters of steroid-oxazole and pharmaceutical compositions containing them
Assignee: Gruppo Lepetit SpA
•
Filing: 1981-04-27
•
Granted: 1984-04-03
•
Expires: 2001-04-27
Abstract
Abstract Water-soluble esters of steroid-oxazole derivatives of formula I <IMAGE> I wherein R is O or a H, ( beta -OH) group, R1 is hydrogen, lower alkyl or phenyl, X is hydrogen, fluorine or chlorine, A stands for a direct carbon-carbon bond or a hydrocarbon chain containing from 1 to 4 carbon atoms, and M is hydrogen or a pharmaceutically acceptable cation are described as well as pharmaceutical compositions containing them particularly suitable for parenteral administration.
Inventors
- 👤 Giangiacomo Nathansohn
- 👤 Giorgio Winters
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 19:23
CPC Classifications
C; C07; C07J; C07J71/00; C07J71/0036; C07J71/0057; C07J71/0068; A; A61; A61P; A61P5/00; A61P5/38
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
7 words
11.beta.,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]-oxazole-3,20-dione-21-hemisuccinate or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
7 words
11.beta.,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]-oxazole-3,20-dione-21-hemisuccinate or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
3 words
11β,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]-oxazole-3,20-dione-21-hemisuccinate sodium salt.
Claim 4
Dependent Claim
3 words
11β,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]-oxazole-3,20-dione-21-hemisuccinate sodium salt.
Claim 5
Dependent Claim
26 words
A pharmaceutical composition for parenteral administration which contains 11β,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione-21-hemisuccinate or a pharmaceutically acceptable salt thereof, as the active ingredient in combination with a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
26 words
A pharmaceutical composition for parenteral administration which contains 11β,21-dihydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione-21-hemisuccinate or a pharmaceutically acceptable salt thereof, as the active ingredient in combination with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-03 | 1987-10-03 | 1988-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-03 | 1991-10-03 | 1992-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-03 | 1995-10-03 | 1996-04-03 | $7700.00 | Window Closed / Lapsed |